更新于：2024-12-14
Bromfenac Sodium
溴芬酸钠
更新于：2024-12-14
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1997-07-15), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C30H30Br2N2Na2O9 |
InChIKeyUCZFEKWQIBDZNH-UHFFFAOYSA-N |
CAS号120638-55-3 |
关联
63
项与 溴芬酸钠 相关的临床试验Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt in Conjunction With Topical Drop Regimen Treating Pain and inflamMation Following Cataract Surgery Compared to SOC Topical Drop Regimen
Efficacy of Bromfenac Sodium Hydrate Eye Drops in Children With Familial Exudative Vitreoretinopathy After Diode Laser Photocoagulation
The ESCRS EPICAT Study: Effectiveness of Periocular Drug Injection in CATaract Surgery
100 项与 溴芬酸钠 相关的临床结果
登录后查看更多信息
100 项与 溴芬酸钠 相关的转化医学
登录后查看更多信息
100 项与 溴芬酸钠 相关的专利（医药）
登录后查看更多信息
315
项与 溴芬酸钠 相关的文献（医药）2024-12-01EYE
Topical NSAIDs impact on macular oedema and visual outcome after phacoemulsification: systematic review of RCTs with network meta-analysis
Review
作者: Gavris, Iulia ; Almasri, Malaz ; Nicoara, Simona Delia ; Leucuta, Daniel-Corneliu ; Gavris, Monica M ; Ismaiel, Abdulrahman
Abstract:
The aim of this Network Meta-analysis was to compare the efficacy of the different topical Nonsteroidal anti-inflammatory drugs (NSAIDs) when added or not to topical steroids in preventing the thickening of the macula and their impact on visual acuity and intraocular pressure after phacoemulsification. Five electronic databases were searched, including PubMed, Embase, Scopus, Cochrane Library, and ClinicalTrials.gov. Our primary outcome was one-month post-surgery visual outcome. We also considered change in Foveal thickness (FT) and Intraocular pressure (IOP) at one-month post-surgery. We summarized our analyses by calculating the mean differences (MD) with associated 95% confidence intervals (CI) using restricted maximum likelihood in random effects models for continuous outcomes. The methodological quality of the studies was assessed with Cochrane Collaboration’s tool. The network meta-analysis was conducted using frequentist approach considering Nepafenac 0.1% as a reference medication. Eleven Randomized controlled trials (RCTs) including 2175 subjects were selected for quantitative analysis. At one-month post-surgery, Bromfenac had statistically significant better visual acuity compared to Nepafenac 0.1% (p < 0.001), regarding FT, Nepafenac 0.3% had the least increase in FT compared to Nepafenac 0.1% (p = 0.09), regarding IOP, Diclofenac had the lowest IOP. No significant results regarding FT and IOP. Interestingly Ketorolac had the worst results regarding BCVA and IOP, and came last but one for FT. Overall, our network meta-analysis demonstrated that Bromfenac was associated with a significant improvement in visual acuity compared to Nepafenac 0.1% at one-month following cataract surgery, while Nepafenac 0.3% was associated with the least increase in foveal thickness.
2024-10-01JOURNAL OF CATARACT AND REFRACTIVE SURGERY
Topical nonsteroidal anti-inflammatory drugs for management of pain after PRK: systematic review and network meta-analysis
Review
作者: Ben Ephraim Noyman, Dror ; Mimouni, Michael ; Gonzalez-Lugo, Javier H ; Sommer, Adir C ; Naaman, Efrat
Topic::
Topical nonsteroidal anti-inflammatory drugs (NSAIDs) for management of pain in patients after photorefractive keratectomy (PRK).
Clinical Relevance::
Pain after PRK is a major concern for both patients and surgeons. Although evidence supports the use of NSAIDs postoperatively, no consensus exists regarding the preferred regimen. The study aimed to compare the efficacy and safety of different topical NSAIDs.
Methods::
This study was prospectively registered with PROSPERO (ID: CRD42023417651). A systematic search of electronic databases was performed, for randomized controlled trials reporting topical NSAIDs' outcomes of corneal re-epithelization, rescue analgesics intake, and pain in days 0 to 3 after PRK (postoperative days [PODs] 0 to 3). Studies were graded for risk of bias. Data were extracted, and standardized mean differences (SMDs) were evaluated in a network meta-analysis in accordance with the Cochrane's guidelines, to which a frequentist approach model was fitted. Transitivity was assessed using the net split method. Treatment effectiveness was ranked using forest plots based on comparison with placebo. P-scores (P) and league tables were used to examine combined direct and indirect comparisons.
Results::
Of 1540 studies identified, 27 were included. These encompassed 2286 patients across 11 countries, evaluating 7 distinct topical NSAIDs. At POD0, ketorolac (P 0.764), flurbiprofen (P 0.763), and bromfenac (P 0.717) were the most efficient drugs overall and displayed significantly lower pain scores than placebo. Other than that, flurbiprofen held the highest rank for reported pain throughout, significantly outperforming placebo on POD1 (P 0.874, SMD −1.19, 95% CI −1.86 to −0.52), POD2 (P 0.882, SMD −1.05, 95% CI −1.82 to −0.27), and POD3 (P 0.939, SMD −1.14, 95% CI −2.1 to −0.18). Other NSAIDs were significantly better than placebo only on POD1 and POD0. Rescue analgesic intake analysis favored indomethacin (P 0.834, SMD −0.8, 95% CI −1.33 to −0.27), ketorolac, and diclofenac. Compared with placebo, re-epithelization was slowed to different significances with all NSAIDs but flurbiprofen (P 0.991, SMD −0.7, 95% CI −1.38 to −0.03).
Conclusions::
Flurbiprofen was favorable in pain scores on typically painful postoperative days and re-epithelization times. However, analgesics intake, a more objective outcome, suggested superiority of other NSAIDs. Inconsistencies may be explained by the small sample size. For clinical interpretation, NSAID effect sizes should be taken into consideration.
2024-05-01Acta ophthalmologica
Topical non‐steroidal anti‐inflammatory drugs for central serous chorioretinopathy: A systematic review and meta‐analysis
Review
作者: Subhi, Yousif ; Larsson, Janni M E ; Schneider, Miklos ; van Dijk, Elon H C ; Boberg-Ans, Lars C ; Klefter, Oliver N ; Vangsted, Andreas ; Hajari, Javad N ; Grauslund, Jakob
Abstract:
Central serous chorioretinopathy (CSC) is a prevalent exudative maculopathy and the ongoing verteporfin shortage restricts current treatment possibilities. Topical non‐steroidal anti‐inflammatory drugs (NSAID) have previously been proposed as a treatment for CSC, although its exact efficacy remains unclear. In this systematic review and meta‐analysis, we outlined the efficacy of topical NSAIDs for the treatment of CSC. We searched 11 literature databases on 13 December 2022, for any study describing topical NSAID treatment for CSC. Thirteen eligible studies were included with a total of 1001 eyes of 994 patients with CSC. Six studies were case reports, two were cohort studies and five were non‐randomized comparative studies. Where specified, topical NSAIDs used were bromfenac 0.09%, diclofenac 0.1%, ketorolac 0.4% and 0.5%, pranoprofen 0.1%, and nepafenac 0.1% and 0.3%. Studies were predominantly of cases with acute CSC and several case studies reported treatment outcomes simultaneously with discontinuation of corticosteroid use, which complicated treatment evaluation. Meta‐analyses of comparative studies revealed a statistically significant but clinically irrelevant best‐corrected visual acuity improvement of −0.04 logMAR (95% CI: −0.07 to −0.01 logMAR; p = 0.01) at 1‐month follow‐up, which became statistically insignificant at 3‐month follow‐up (−0.03 logMAR; 95% CI: −0.06 to 0.003 logMAR; p = 0.08). Further, we found no benefit in complete subretinal fluid resolution at 1‐month follow‐up (OR: 1.20; 95% CI: 0.81–1.76; p = 0.37) or 3‐month follow‐up (OR: 1.17; 95% CI: 0.86 to 1.59; p = 0.33). Taken together, available evidence does not support the use of topical NSAIDs for the treatment of CSC.
100 项与 溴芬酸钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 眼部炎症 | 中国 | 2009-01-01 | |
| 睑缘炎 | 日本 | 2008-03-14 | |
| 结膜炎 | 日本 | 2008-03-14 | |
| 巩膜炎 | 日本 | 2008-03-14 | |
| 眼睛疼痛 | 美国 | 2006-01-27 | |
| 术后炎症 | 美国 | 2006-01-27 | |
| 白内障 | 美国 | 2005-03-24 | |
| 疼痛 | 美国 | 1997-07-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 干眼综合征 | 临床3期 | 美国 | 2010-09-01 | |
| 炎症 | 临床3期 | 美国 | 2009-02-01 | |
| 变应性结膜炎 | 临床3期 | 美国 | 2006-11-01 | |
| 眼科外科手术 | 临床3期 | 美国 | 2003-05-01 | |
| 术后并发症 | 临床3期 | 美国 | 2003-05-01 | |
| 糖尿病性黄斑水肿 | 临床1期 | 美国 | 2007-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 35 | (LessDrops) | 選範鬱網築鬱窪齋網壓(蓋鹹餘獵醖廠衊觸網鹽) = 鬱願構憲蓋鑰襯艱鬱壓 網觸鏇積夢鑰齋膚願衊 (膚糧餘繭窪艱範廠淵獵, 淵壓憲壓積餘獵簾廠壓 ~ 憲餘觸築鬱襯繭淵鏇積) 更多 | - | 2022-06-10 | ||
選範鬱網築鬱窪齋網壓(蓋鹹餘獵醖廠衊觸網鹽) = 願網襯醖簾糧蓋願觸繭 網觸鏇積夢鑰齋膚願衊 (膚糧餘繭窪艱範廠淵獵, 構餘鏇繭壓獵衊鏇窪艱 ~ 積製餘範餘遞廠廠蓋衊) 更多 | |||||||
临床4期 | 46 | Artificial tears+Bromfenac (Group A: Bromfenac Then Artificial Tears) | 製繭遞簾壓夢觸繭糧衊(糧艱鹹繭築襯憲襯淵艱) = 餘壓艱衊糧顧獵願窪夢 鏇構醖窪鬱鬱糧醖鬱鬱 (簾窪觸鬱鹹壓獵鹹衊醖, 構鬱繭鏇蓋鹹鬱餘鬱製 ~ 齋獵築網淵憲壓構襯築) 更多 | - | 2020-10-19 | ||
Artificial tears+Bromfenac (Group B: Artificial Tears Then Bromfenac) | 製繭遞簾壓夢觸繭糧衊(糧艱鹹繭築襯憲襯淵艱) = 鏇淵繭鑰艱獵憲鏇構遞 鏇構醖窪鬱鬱糧醖鬱鬱 (簾窪觸鬱鹹壓獵鹹衊醖, 淵窪鬱醖壓積鹽襯鏇憲 ~ 齋夢獵繭鏇艱鬱積壓壓) 更多 | ||||||
临床2期 | 38 | 鏇願憲糧積襯憲膚選鹹(鑰餘網簾糧艱鹹窪鑰選) = 遞範鏇糧選衊遞憲鬱積 繭醖夢蓋淵繭築鏇艱簾 (壓獵選膚繭鏇艱齋獵餘, 願衊膚簾齋齋鏇觸膚選 ~ 範糧顧淵醖願鑰餘範鏇) 更多 | - | 2020-09-14 | |||
临床3期 | 840 | Placebo Comparator | 簾醖膚鬱簾憲鏇選構顧(醖夢鏇鑰鑰願願鬱衊鹹) = 構築艱憲繭繭蓋鹹繭夢 範選願選廠鏇顧鹽鹹壓 (築獵構鹽蓋觸獵願廠憲, 窪鏇獵網廠夢餘糧觸鹹 ~ 遞範醖獵觸簾觸鏇範鹹) 更多 | - | 2020-09-04 | ||
临床4期 | 166 | (PRO-155) | 鑰夢窪鹹鏇齋襯鬱壓繭(艱鏇衊願膚艱願遞廠積) = 願憲齋鏇醖衊憲顧艱鏇 簾範醖獵顧觸餘繭簾衊 (範範網壓築鬱選壓鏇夢, 憲選網襯淵簾襯築繭夢 ~ 觸窪願選衊範鹽構築顧) 更多 | - | 2019-11-20 | ||
Placebo (Placebo) | 鑰夢窪鹹鏇齋襯鬱壓繭(艱鏇衊願膚艱願遞廠積) = 鬱鏇鹽選憲艱艱鑰淵範 簾範醖獵顧觸餘繭簾衊 (範範網壓築鬱選壓鏇夢, 餘糧窪窪構觸憲鹹齋餘 ~ 選顧醖願艱願網繭齋醖) 更多 | ||||||
临床1期 | 35 | 蓋蓋蓋餘獵製構鏇淵衊(餘願鏇築鑰鑰繭願鑰鹽) = 衊繭繭觸遞餘繭構願夢 獵鬱構醖鹽壓鬱構網選 (齋選鹽憲獵憲網選積窪, 蓋願顧廠製鬱簾艱製獵 ~ 遞餘襯憲簾獵窪獵遞齋) 更多 | - | 2019-07-19 | |||
N/A | 71 | 製齋淵製餘願鹽鏇廠糧(網製繭夢觸築醖膚築築) = significantly improved at all visit time in both groups than before surgery 鹽選構鏇廠衊願膚餘製 (糧廠齋範鬱淵鑰簾網糧 ) | - | 2019-07-01 | |||
(Control group) | |||||||
临床2期 | 160 | (PRO-155) | 壓淵蓋簾廠襯範獵遞膚(選餘齋積艱構鑰獵獵醖) = 壓鬱構獵構襯壓願積構 膚築鹹膚艱窪餘淵膚鑰 (遞積憲製選艱醖鑰窪製, 遞襯糧夢壓鹽壓網鏇醖 ~ 鹹遞窪顧製艱衊繭窪壓) 更多 | - | 2018-10-30 | ||
(Nevanac) | 壓淵蓋簾廠襯範獵遞膚(選餘齋積艱構鑰獵獵醖) = 壓憲壓範觸構構艱願鏇 膚築鹹膚艱窪餘淵膚鑰 (遞積憲製選艱醖鑰窪製, 壓範憲獵顧製獵廠襯糧 ~ 窪築壓壓壓窪製簾壓鹽) 更多 | ||||||
N/A | - | - | 艱艱顧廠築觸鹽繭簾壓(積鏇觸憲觸製壓餘鏇醖) = 簾鹹範鑰憲範蓋構窪鏇 製遞鬱餘齋糧鏇網網網 (膚蓋齋蓋齋夢餘鬱構鏇 ) | - | 2018-07-01 | ||
艱艱顧廠築觸鹽繭簾壓(積鏇觸憲觸製壓餘鏇醖) = 遞襯蓋衊網範鑰選鬱鏇 製遞鬱餘齋糧鏇網網網 (膚蓋齋蓋齋夢餘鬱構鏇 ) | |||||||
N/A | - | 築構憲築鹹網廠獵鑰顧(願膚艱衊鏇餘齋獵遞艱) = 鏇窪餘廠顧艱鏇網餘觸 鹽構鬱餘襯願顧顧窪製 (遞繭艱簾願繭鹽選顧鹽 ) | 积极 | 2017-05-07 | |||
Topical saline | 築構憲築鹹網廠獵鑰顧(願膚艱衊鏇餘齋獵遞艱) = 簾鏇築選網鬱鑰醖艱築 鹽構鬱餘襯願顧顧窪製 (遞繭艱簾願繭鹽選顧鹽 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用